| abstract |
The present invention relates to formula (I) wherein R 1 and R 2 are the same or different and represent a hydrogen atom, a C 1 -C 5 alkyl group or a halogen atom, or have 3 to 7 bonds together with carbon atoms of the chain A ring, R 3 represents a C 1 -C 5 alkyl group or a partially or fully fluorinated C 1 -C 5 alkyl group, A is an optionally substituted monocyclic or bicyclic aromatic ring, an ester group -COOR 4 , Alkenyl group -CR 5 = CR 6 R 7 , alkynyl group -C≡CR 5 or a partially or fully fluorinated C 1 -C 5 alkyl group, B represents a carbonyl group or a CH 2 group, and Ar represents a partial formula 2 to And a nonsteroidal gestagen of a ring system selected from the group of 11). When B in the formula (I) represents a CH 2 group, Ar further means a phenyl radical of part (12). The novel compounds exhibit a very strong affinity for gestagen receptors. It may be used alone or in combination with estrogen in contraceptive preparations. It may also be used for the treatment of endometriosis. It can be used with estrogen in formulations for the treatment of gynecological diseases. It may also be used to treat premenstrual appeal and also in long-term replacement therapy. Its androgen activity can allow it to be used for male fertility control and male HRT and also for treating androgenic syndrome. |